Salvage therapy with the combination of ARA-C and gemtuzumab ozogamicin in post-allo-SCT high risk aml patients is feasible and results in modest responses

Category Primary study
JournalBlood
Year 2012
This article has no abstract
Epistemonikos ID: d0da8d31cf03ad99d5532ea4da65705cdc4bd37b
First added on: Feb 05, 2025